CRISPR Therapeutics AG

CRISPR Therapeutics AG

CRSP· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +33.2% in FY2025

Samarth Kulkarni, Ph.D is the CEO of CRISPR Therapeutics AG and was paid $7.7M in FY2025 (Dec), down 77%.

Pay$100 in the stock at the end of FY20 → $34
CEO pay is from each CRISPR Therapeutics AG proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Samarth Kulkarni, Ph.DFY2025
  2. 2Naimish Patel, M.D.FY2025
  3. 3Julianne Bruno, M.B.A.FY2025
  4. 4Raju Prasad, Ph.D.FY2025
  5. 5James R. KasingerFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

CRISPR Therapeutics AG paid its 5 named executives $22.1M in total in FY2025 (Dec). CEO Samarth Kulkarni, Ph.D was paid $7.7M of that.

Name
Samarth Kulkarni, Ph.DChairman and Chief Executive Officer
Naimish Patel, M.D.Chief Medical OfficerNot disclosed
Julianne Bruno, M.B.A.Former Chief Operating OfficerNot disclosed
Raju Prasad, Ph.D.Chief Financial Officer
James R. KasingerGeneral Counsel

of each named executive, from the Summary Compensation Table of each proxy.

Peers19

See all

The FY2023 (Dec) proxy of CRISPR Therapeutics AG names 19 peer companies for pay. Among CRISPR Therapeutics AG and these peers, CEO pay was 3rd highest of 6 and total shareholder return was 5th highest of 6.

3rd highest of 6in CRISPR Therapeutics AG and its pay peers, FY2023 (Dec) by CEO pay:

$6.3M$15.8M

5th highest of 6in CRISPR Therapeutics AG and its pay peers, FY2023 (Dec) by total shareholder return:

$84$166

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board7

See all
  • Douglas A. Treco, Ph.D.Lead independent director · 3 yr on the boardIndependentAudit, Directors and Executive, Nominating and Corporate Governance—Paid as an executive
  • Ali BehbahaniDirector · 8 yr on the boardIndependentDirectors and Executive, Nominating and Corporate Governance—Paid as an executive
  • John T. GreeneDirector · 4 yr on the boardIndependentAudit (Chair), Directors and Executive—Paid as an executive
  • Katherine A. High, M.D.Director · 4 yr on the boardIndependentDirectors and Executive, Nominating and Corporate Governance—Paid as an executive
  • H. Edward Fleming, Jr., M.D.Director · 2 yr on the boardIndependentDirectors and Executive—Paid as an executive
  • Maria Fardis, Ph.D.Director · 1 yr on the boardIndependentAudit, Directors and Executive—Paid as an executive

The board of the latest proxy (FY2023).

Shared directors

Activity

  1. Pay
    CRISPR Therapeutics AG CEO pay fell 77% to $7.7M. The stock rose 33% in FY2025 (Dec).
    DEF 14A
  2. Pay
    CRISPR Therapeutics AG CFO pay fell 35% to $3.6M. The stock rose 33% in FY2025 (Dec).
    DEF 14A
  3. Pay
    CRISPR Therapeutics AG Division head pay fell 32% to $4.3M. The stock rose 33% in FY2025 (Dec).
    DEF 14A
  4. Pay
    CRISPR Therapeutics AG Former Chief Operating Officer pay fell 16% to $3.7M. The stock rose 33% in FY2025 (Dec).
    DEF 14A
  5. Pay
    CRISPR Therapeutics AG General counsel pay fell 53% to $2.9M. The stock rose 33% in FY2025 (Dec).
    DEF 14A
  6. Pay
    CRISPR Therapeutics AG CEO pay rose 169% to $33.2M. The stock fell 37% in FY2024 (Dec).
    DEF 14A
  7. Pay
    CRISPR Therapeutics AG General counsel pay rose 74% to $6.1M. The stock fell 37% in FY2024 (Dec).
    DEF 14A
  8. Pay
    CRISPR Therapeutics AG CEO pay fell 41% to $12.3M. The stock rose 54% in FY2023 (Dec).
    DEF 14A
  9. Pay
    CRISPR Therapeutics AG CEO pay rose 22% to $20.7M. The stock fell 46% in FY2022 (Dec).
    DEF 14A
  10. Pay
    CRISPR Therapeutics AG President pay rose 192% to $555.1K. The stock rose 54% in FY2023 (Dec).
    DEF 14A
  11. Pay
    CRISPR Therapeutics AG General counsel pay fell 29% to $3.5M. The stock rose 54% in FY2023 (Dec).
    DEF 14A
  12. Pay
    CRISPR Therapeutics AG Former Chief Medical Officer pay fell 45% to $3.2M. The stock rose 54% in FY2023 (Dec).
    DEF 14A
  13. Pay
    CRISPR Therapeutics AG Former CFO pay fell 97% to $114.8K. The stock rose 54% in FY2023 (Dec).
    DEF 14A
  14. Pay
    CRISPR Therapeutics AG Former CFO pay fell 45% to $4.1M. The stock fell 46% in FY2022 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 21, 2026FY2025
Annual report10-KFeb 12, 2026FY2025
Proxy statementDEF 14AApr 16, 2025FY2024
Annual report10-KFeb 11, 2025FY2024
Proxy statementDEF 14AApr 9, 2024FY2023
Annual report10-KFeb 21, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data